scholarly journals Complete Remission of Advanced Adrenocortical Cancer Following Mitotane Monotherapy: A Case Report and Literature Review of Predictive Markers

2021 ◽  
Vol 11 ◽  
Author(s):  
Judit Tőke ◽  
Zsuzsanna Jakab ◽  
Júlia Stark ◽  
Gergely Huszty ◽  
Péter Reismann ◽  
...  
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Complete Remission ◽  
Vascular Invasion ◽  
Ct Scans ◽  
Adrenocortical Cancer ◽  
High Power Field ◽  
Predictors Of Response ◽  
Number Of Patients ◽  
Work Up

Mitotane has been used for the treatment of adrenocortical cancer (ACC) for over 50 years. Despite its widespread use both in monotherapy and in combination with chemotherapeutics, our knowledge of its mechanism of action and therapeutic efficacy is scarce. The number of patients with advanced ACC who have achieved complete remission documented by detailed clinical data is below ten. We report a case of a 64-year-old woman with a non-functional ACC. Histological examination showed vascular invasion, Ki67 of 10% and a mitotic count of 3/10 high-power field. Immunohistochemistry revealed p53 positivity. Pathological TNM grade was reported as T2N0M0, ENSAT stage 2. Nine months after the initial diagnosis, re-staging CT revealed multiple peritoneal nodules, lymph node and kidney metastases confirmed by histologic examination. Mitotane monotherapy was started with a maintenance dose between 2.0 and 2.5 grams/day. Partial remission was established at six months. Subsequently, for another 12 months, each of the three-monthly CT scans confirmed complete remission. Nineteen months after the initiation of mitotane, an unexpected sudden death occurred. A detailed autopsy work-up, performed in the full awareness of oncological history, confirmed complete remission. The authors review the molecular biomarkers and clinical features reported as predictors of response to mitotane monotherapy.

Contemporary Chemotherapy and Radiotherapy for Inguinal Metastases of Carcinoma of the Penis: A Case Report

1988 ◽  
Vol 74 (5) ◽  
pp. 585-586 ◽  
Author(s):  
Giovannella Palmieri ◽  
Cesare Gridelli ◽  
Alberto Vitale ◽  
Angelo Raffaele Bianco
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Complete Remission ◽  
Lymph Node Metastases ◽  
Node Metastases ◽  
Disease Free ◽  
Cancer Of The Penis

A case is reported of a 76 year old patient with inoperable lymph node metastases from cancer of the penis. Methotrexate and bleomycin chemotherapy and concurrent irradiation were administered. The patient achieved a complete remission and is disease-free 30 months after therapy. The treatment was well tolerated.

scholarly journals Inoperábilis periauricularis daganat sikeres sugárkezelése

2015 ◽  
Vol 156 (40) ◽  
pp. 1625-1627
Author(s):  
Andrea Furka ◽  
Imre Szabó ◽  
Erika Hevesi ◽  
Zsolt Adamecz ◽  
Éva Pintye
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Complete Remission ◽  
Diabetic Patient ◽  
Initial Treatment ◽  
Adjuvant Radiotherapy ◽  
R1 Resection ◽  
Skin Cancers ◽  
First Choice ◽  
Choice Of Treatment

Surgery has been considered the first choice of treatment in planocellular skin cancers. However, adjuvant radiotherapy is often required in R1 resection or in lymph node positivity. Inoperable cases are also treated with ionizing radiation with palliative purpose. The authors present a case report of a successful treatment of an 87-year-old diabetic patient with a T4N1M0 stage periauricular destructive tumour treated with 3D conformal adaptive radiotherapy. Complete remission occurred although the initial treatment aim was only palliation. Orv. Hetil., 2015, 156(40), 1625–1627.

Prognostic Value of Lymphography in Cervical Cancer

1978 ◽  
Vol 64 (3) ◽  
pp. 295-304 ◽  
Author(s):  
Fabio Volterrani ◽  
Stefania Vona ◽  
Sandro Barni ◽  
Renato Musumeci
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Clinical Stage ◽  
Stage I ◽  
Clinical Classification ◽  
Therapeutic Approaches ◽  
Number Of Patients ◽  
Node Metastases ◽  
Diagnostic Work ◽  
Work Up

This work is based on a review of 341 lymphographies carried out as a part of the initial diagnostic work-up performed on the same number of patients referred to our Institute for treatment from January 1961 to December 1976. As regards the distribution by clinical stage of the cases under consideration, there were 152 cases in Stage I (44.6%), 100 in Stage II (29.3%) and 89 in Stages III plus IV (26.1%). The positive lymphography incidence at the 2 extremes (Stage I a and Stages III plus IV) was 3.5 % and 46.0 %, respectively. The histologic type on its own did not seem to influence the incidence of lymph node metastases detectable by lymphography. For the negative cases, with all the stages mixed together, a 68.8 % 5-year survival rate free of disease was recorded, as compared with the 32.0 % found for the positive cases (P < 0.0001). A similar difference was recorded stage by stage. Our observations support the opinion that lymphography is valid in clinical practice to distinguish the minimum or nil lymph node invasion cases (negative) with favorable prognosis, from the cases having lymph node invasion of a certain importance or even at a maximum (positive), with a poor fate, independently of the initial clinical stage. Furthermore they suggest the advisability of reviewing the basic concepts of the clinical classification in cervical cancer, to be cautious in considering clinical reviews that do not report information of this importance, and to put under discussion different therapeutic approaches for cases presenting a lymphographic abnormality.

scholarly journals A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Hiroyuki Tani ◽  
Ryo Miyamoto ◽  
Syunya Noguchi ◽  
Sena Kurita ◽  
Tomokazu Nagashima ◽  
...  
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Malignant Melanoma ◽  
Tyrosine Kinases ◽  
Kinase Inhibitor ◽  
Metastatic Lymph Node ◽  
Clinical Signs ◽  
Number Of Patients ◽  
Vitro Analysis

Abstract Background Canine malignant melanoma is highly aggressive and generally chemoresistant. Toceranib is a kinase inhibitor drug that inhibits several tyrosine kinases including the proto-oncogene receptor tyrosine kinase KIT. Although canine malignant melanoma cells often express KIT, a therapeutic effect for toceranib has yet to be reported for this tumor, with only a small number of patients studied to date. This is a case report of a dog with malignant melanoma that experienced a transient response to toceranib. Furthermore, the KIT expressed in the tumor of this case was examined using molecular analysis. Case presentation A Shiba Inu dog presented with a gingival malignant melanoma extending into surrounding structures with metastasis to a submandibular lymph node. The dog was treated with toceranib (Palladia®; 2.6–2.9 mg/kg, orally, every other day) alone. Improvement of tumor-associated clinical signs (e.g., halitosis, tumor hemorrhage, trismus, and facial edema) with reduced size of the metastatic lymph node was observed on Day 15. The gingival tumor and associated masses in the masseter and pterygoid muscles decreased in size by Day 29 of treatment. Toceranib treatment was terminated on Day 43 due to disease progression and the dog died on Day 54. The tumor of this dog had a novel deletion mutation c.1725_1733del within KIT and the mutation caused ligand-independent phosphorylation of KIT, which was suppressed by toceranib. This mutation was considered to be an oncogenic driver mutation in the tumor of this dog, thereby explaining the anti-tumor activity of toceranib. Conclusions This is the first report that presents a canine case of malignant melanoma that responded to toceranib therapy. KIT encoded by KIT harboring a mutation c.1725_1733del is a potential therapeutic target for toceranib in canine malignant melanoma. Further investigation of the KIT mutation status and toceranib therapy in canine malignant melanoma will need to be undertaken.

Popliteal nodal metastasis from squamous cell cancer of the foot. Case report and literature review

2019 ◽  
pp. 1-2
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Literature Review ◽  
Squamous Cell ◽  
Rare Case ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Nodal Metastasis ◽  
Regional Disease ◽  
The Right

We report a very rare case of squamous cell cancer of the right foot which had metastasize to the ipsilateral popliteal lymph node after initial diagnosis and treatment for the loco-regional disease.

Sign in / Sign up

Export Citation Format

Share Document